AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 28 - (NewsRx.com & NewsRx.net) -- Vical, Inc., (VICL) announced that the company has been awarded a contract to manufacture clinical-grade supplies of an experimental DNA vaccine against Ebola for initial clinical development planned by the Dale and Betty Bumpers Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Vical's president and CEO, Vijay B. Samant, said, "Over the last several years, Vical has developed significant expertise and infrastructure, and has become recognized as a reliable manufacturer of clinical-grade (cGMP) plasmid DNA. We are pleased to support the VRC's Ebola vaccine program, which has potential for prevention of both the naturally occurring and weaponized forms. The beauty of using Vical's technology platform for such virulent agents is that development and production of vaccines do not involve any handling of the pathogen itself."
"Our colleagues at the VRC and other investigators have demonstrated in a variety of animal models that gene-based vaccines can induce protective immunity to lethal challenge by Ebola viruses," said Vical's chief scientific officer, David C. Kaslow, MD. "With the recent issuance of the 'two animal rule' by the FDA, a new path has emerged for demonstrating effectiveness of new products, such as Ebola vaccines, ...
Source: HighBeam Research, Vical Receives U.S. government contract to manufacture Ebola...